EUVIMEDEUVIMED entdecken
Crossref

JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms

Andrea Arena, Maria Anele Romeo, Rossella Benedetti, Maria Saveria Gilardini Montani, Mara Cirone

Experimental Hematology · 2023

DOI: 10.1016/j.exphem.2022.12.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Experimental Hematology, 2023. Verfasst von Andrea Arena und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Antineoplastic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple myeloma (MM) and primary effusion lymphoma (PEL) are two aggressive hematologic cancers against which bortezomib and JQ-1, proteasome and bromodomain and extraterminal domain (BET) inhibitors, respectively, have been shown to have a certain success. However, the combination of both seems to be more promising than the single treatments against several cancers, including MM. Indeed, in the latter, proteasome inhibition upregulated nuclear respiratory factor 1 (NRF1), and such a prosurvival effect was counteracted by BET inhibitors. In the present study, we found that JQ-1/bortezomib induced a strong cytotoxic effect against PEL and discovered new insights into the cytotoxic mechanisms induced by such a drug combination in PEL and MM cells. In particular, a stronger c-Myc downregulation, leading to increased DNA damage, was observed in these cells after treatment with JQ-1/bortezomib than after treatment with the single drugs. Such an effect contributed to mechanistic target of rapamycin (mTOR)-phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 (p-4EBP1) axis inhibition, also occurring through c-Myc downregulation. However, besides the prodeath effects, JQ-1/bortezomib activated unfolded protein response (UPR) and autophagy as prosurvival mechanisms. In conclusion, this study demonstrated that JQ-1/bortezomib combination could be a promising treatment for MM and PEL, unveiling new molecular mechanisms underlying its cytotoxic effect, and suggested that UPR and autophagy inhibition could be exploited to further potentiate the cytotoxicity of JQ-1/bortezomib.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntineoplastic AgentsHumansBortezomibProteasome Endopeptidase ComplexTOR Serine-Threonine KinasesCell Line, TumorApoptosis

Substanzen

BortezomibProteasome Endopeptidase ComplexAntineoplastic AgentsTOR Serine-Threonine KinasesMTOR protein, human

Autor:innen und Institutionen

  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
  • Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy. Electronic address: mara.cirone@uniroma1.it.

Zitieren

APA

Arena, A., Romeo, M. A., Benedetti, R., Gilardini Montani, M. S., & Cirone, M. (2023). JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms. Experimental Hematology. https://doi.org/10.1016/j.exphem.2022.12.007

Vancouver

Arena A, Romeo MA, Benedetti R, Gilardini Montani MS, Cirone M. JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms. Experimental Hematology. 2023. doi:10.1016/j.exphem.2022.12.007

BibTeX
@article{Arena2023,
  author = {Arena, Andrea and Romeo, Maria Anele and Benedetti, Rossella and Gilardini Montani, Maria Saveria and Cirone, Mara},
  title = {JQ-1/bortezomib combination strongly impairs MM and PEL survival by inhibiting c-Myc and mTOR despite the activation of prosurvival mechanisms},
  journal = {Experimental Hematology},
  year = {2023},
  doi = {10.1016/j.exphem.2022.12.007}
}
Kostenlos starten →